Characteristics of systematic reviews evaluating treatments for COVID-19 registered in PROSPERO
| Autor: | Rongna Lian, Dairong Xie, Jinhui Tian, Ruinian Zhang, Ya Gao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Internationality Databases Factual Epidemiology research collaboration medicine.medical_treatment Psychological intervention MEDLINE Traditional Chinese medicine Antiviral Agents outcome measures 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine systematic review Internal medicine medicine Humans 030212 general & internal medicine Intersectoral Collaboration Original Paper Rehabilitation treatment SARS-CoV-2 business.industry Ribavirin Mortality rate COVID-19 Hydroxychloroquine Treatment Outcome Infectious Diseases Systematic review chemistry business 030217 neurology & neurosurgery Systematic Reviews as Topic medicine.drug |
| Zdroj: | Epidemiology and Infection |
| ISSN: | 1469-4409 0950-2688 |
| DOI: | 10.1017/s0950268821001321 |
| Popis: | Characteristics and research collaboration of registered systematic reviews (SRs) on treatment modalities for coronavirus disease-2019 (COVID-19) remain unclear. This study analysed research collaboration, interventions and outcome measures in registered SRs on COVID-19 treatments and pointed out the relevant problems. PROSPERO (international prospective register of systematic reviews) was searched for SRs on COVID-19 treatments as of 2 June 2020. Excel 2016 was used for descriptive analyses of the extracted data. VOSviewer 1.6.14 software was used to generate network maps for collaborations between countries and institutions. A total of 189 SRs were included, which were registered by 301 institutions from 39 countries. China (69, 36.50%) exhibited the highest output. Cooperation between countries was not close enough. As an institution, the Chengdu University of Traditional Chinese Medicine (7, 3.70%) had the highest output. There was close cooperation between institutions. Interventions included antiviral therapy (81, 42.86%), respiratory support (16, 8.47%), circulatory support (11, 5.82%), plasma therapy for convalescent patients (11, 5.82%), immunotherapy (9, 4.76%), TCM (traditional Chinese medicine) treatment (9, 4.76%), rehabilitation treatment (5, 2.65%), anti-inflammatory treatment (16, 8.47%) and other treatments (31, 16.40%). Concerning antiviral therapy (81, 42.86%), the most commonly used antiviral agents were chloroquine/hydroxychloroquine (26, 13.76%), followed by remdesivir (12, 6.35%), lobinavir/ritonavir (11, 5.82%), favipiravir (5, 2.65%), ribavirin (5, 2.65%), interferon (5, 2.65%), abiron (4, 2.12%) and abidor (4, 2.12%). The most frequently used primary and secondary outcomes were the mortality rate (92, 48.68%) and hospital stay length (48, 25.40%), respectively. The expression of the outcomes was not standardised. Many COVID-19 SRs on treatment modalities have been registered, with a low completion rate. Although there was some collaboration between countries and institutions in the currently registered SRs on treatment modalities for COVID-19 on PROSPERO, cooperation between countries should be further enhanced. More attention should be directed towards identifying deficiencies of outcome measures, and the standardisation of results should be maximised. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|